Sartorius Stedim Biotech

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
  • TickerDIM
  • ISINFR0013154002
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance
Jehanne Leroy

Sartorius Stedim Biotech - AGM du 24 mars 2021

Rémunérations 2020 (résolution 7) : Les montants attribués au titre de l’exercice 2020 à M. Kreuzburg sont acceptables et bien en ligne avec les bonnes performances du groupe sur l’exercice. Nous soutenons donc la résolution 7. Nous encourageons toutefois la société à améliorer sa transparence et à communiquer les taux de réalisation de chacun des critères du bonus comme c’est désormais la pratique dans le SBF 120. Rapport rémunérations (résolution 6)S’il est appréciable que la société ait entendu les remarques de Proxinvest et ait communiqué cette année les ratios d’équité, on regrettera tou...

Thomas J. Schiessle

Sartorius - Very strong growth - Expectations for 2025 upgraded

Very strong growth - Expectations for 2025 upgraded The very strong and highly profitable sales growth at the end of 2020 exceeded the guidance raised three times in 2020. All regions expanded > 26% year-on-year. Healthcare customer markets (BU BPS) remain very expansionary. COVID-19 does not (yet) displace any therapeutic projects to a significant extent. Industrial customers (BU LPS) are investing more and more (especially in EMEA) and are investing more and more in COVID-19. The "Sartorius 2025" strategy, which has been in force since 2/18, has now been raised in January.

Thomas J. Schiessle

Sartorius - Sehr kräftiges Wachstum – Erwartungen für 2025 hochgestuft

Das zum Jahresschluss 2020 sehr kräftige und hochprofitable Umsatzwachstum hat die 2020 dreimal angehobene Guidance übertroffen. Alle Regionen expandierten > 26 % ggü. Vj. Die Healthcare-Kundenmärkte (BU BPS) bleiben sehr expansiv. COVID-19 verdrängt (noch) keine therapeutischen Projekte in nennenswertem Umfang. Die Industrie-Kunden (BU LPS) investieren (insbesondere in EMEA) mehr und mehr wg. COVID-19. Die seit 2/18 gültige Strategie „Sartorius 2025“ wurde jetzt im Januar angehoben.

Jean-Baptiste Rouphael ...
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/27/2021

...

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : Q4 2020/FY 2020 still robust and a slight momentum effect

>Q4 2020 in line with the consensus - Q4 sales were € 530.6m, i.e. +45.8% and +47% cc. Q4 EBITDA was € 170m (31% of sales).For the full year, sales at SSB therefore came in at € 1,910m (+34.6% of which +6% linked to acquisitions) for EBITDA of € 605m.For 2021, the group is targeting growth of 20% to 26% i.e. around € 2,294-2,410m (consensus: € 2,363m) and a margin of 32% (i.e. € 734-770m/consensus: € 742m).For 2025, SSB is targeting sales of € 3.8bn (v...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Sector Synopsis

Int'l Equity Strategy Global equities were on a tear in early January, continuing the trend that began in 4Q2019. As global equities started to get extended, the coronavirus outbreak hit in mid-January, leading to some market setbacks and deterioration in market indicators as global growth expectations were dialed-in. Despite this deterioration, what was important to us was that there were not any breakdowns. Even the areas of the market most-directly affected by the outbreak -- China (MSCI China) and EM (MSCI EM) -- were not breaking down. To us, this was a reassuring sign of underlying stre...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

EM Pullback Opportunity Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as there is no significant additional damage, we view recent weakness as a buying opportunity - especially ...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Sector Synopsis

Int'l Equity Strategy In using technical analysis, we let the market be our guide. That is, we analyze what is true in the market, utilizing the vast array of tools in our technical analysis toolbox which we then formulate into our outlook using a weight of the evidence approach. In a world where there are no shortages of things to worry about (trade wars, central banks, Trump impeachment, negative interest rates, low global growth, Brexit, Manufacturing weakness, elections, Hong Kong protests, the list goes on...), our tools help us cut through the noise and conjecture. After all, what if th...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Global Equity Strategy

Int'l Equity Strategy Global equities staged an impressive rally over the first four months of 2019. The nearly unabated advance allowed the broad major indexes (MSCI ACWI, ACWI ex-US, and EAFE) to break topside critical 14-month downtrends which began in January 2018. Heading into May, YTD uptrends were ubiquitous and market participants were generally of the belief that a US-China trade deal was a foregone conclusion. Then came Trump's May 5th tweets claiming China was attempting to renegotiate, and that tariffs would increase from 10% to 25%. The tariff escalation contributed to uptrend br...

Jérôme VINERIER

Short term view - SARTORIUS STEDIM BIOTECH : The background trend is clearly bullish.

The background trend is clearly bullish. The recent fall is a consolidation that may be interrupted as it approaches de €97.70. The next target is at €120.50. The trend would be invalidated below the support at €80.80.

Sartorius Stedim Biotech S.A.: 1 director sold

A director at Sartorius Stedim Biotech S.A. sold 405,887 shares at 327.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

Thomas J. Schiessle

Sartorius - Very strong growth - Expectations for 2025 upgraded

Very strong growth - Expectations for 2025 upgraded The very strong and highly profitable sales growth at the end of 2020 exceeded the guidance raised three times in 2020. All regions expanded > 26% year-on-year. Healthcare customer markets (BU BPS) remain very expansionary. COVID-19 does not (yet) displace any therapeutic projects to a significant extent. Industrial customers (BU LPS) are investing more and more (especially in EMEA) and are investing more and more in COVID-19. The "Sartorius 2025" strategy, which has been in force since 2/18, has now been raised in January.

Thomas J. Schiessle

Sartorius - Sehr kräftiges Wachstum – Erwartungen für 2025 hochgestuft

Das zum Jahresschluss 2020 sehr kräftige und hochprofitable Umsatzwachstum hat die 2020 dreimal angehobene Guidance übertroffen. Alle Regionen expandierten > 26 % ggü. Vj. Die Healthcare-Kundenmärkte (BU BPS) bleiben sehr expansiv. COVID-19 verdrängt (noch) keine therapeutischen Projekte in nennenswertem Umfang. Die Industrie-Kunden (BU LPS) investieren (insbesondere in EMEA) mehr und mehr wg. COVID-19. Die seit 2/18 gültige Strategie „Sartorius 2025“ wurde jetzt im Januar angehoben.

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : Q4 2020/FY 2020 still robust and a slight momentum effect

>Q4 2020 in line with the consensus - Q4 sales were € 530.6m, i.e. +45.8% and +47% cc. Q4 EBITDA was € 170m (31% of sales).For the full year, sales at SSB therefore came in at € 1,910m (+34.6% of which +6% linked to acquisitions) for EBITDA of € 605m.For 2021, the group is targeting growth of 20% to 26% i.e. around € 2,294-2,410m (consensus: € 2,363m) and a margin of 32% (i.e. € 734-770m/consensus: € 742m).For 2025, SSB is targeting sales of € 3.8bn (v...

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : T4 2020 / FY 2020 toujours aussi robuste et léger effet momentum

>T4 2020 en ligne avec le CS - Le CA T4 se monte à 530.6 M€, soit +45.8% et +47% à tcc. L’EBITDA T4 ressort à 170 M€ (31% du CA).Sur l’année, les revenus de SSB atteignent donc 1 910 M€ (+34,6% dont +6% lié aux acquisitions) pour un EBITDA de 605 M€.Pour 2021, la société guide sur une croissance de 20% à 26% soit env. 2 294-2 410 M€e (CS : 2 363 M€e) et une marge de 32% (soit 734-770 M€e / CS : 742 M€e)Pour 2025, SSB vise un CA de 3,8 Md€ (vs 3,5 Md€ a...

Thomas J. Schiessle

Vorbereitungen für COVID-19-Vaccine bringt Orderschub von 60 % in Q3/20 - 4. Guidance-Anpassung für Gj. 2020

Überraschend kräftig entwickelte sich Q3/20; BPS (+26 % auf € 144,5 Mio.) wuchs anhaltend zweistellig; LPS (+44,1 % auf € 478,7 Mio.) beendete (mit Wiedereröffnung der akademischen Labore) die Schwächephase des H1/20 in allen Regionen. Der Ordereingang erreichte € 711,7 Mio. (+54,5% ggü. Vj; in CC: +60% - davon ca. 30%-Punkte COVID-19-bedingt). Der Q3/20-Konzern­umsatz stieg um +39,5 % ggü. Vj. (EMEA: +37,4%; Amerika: +38,7 %; Asia/Pacific:  +27,3 %) auf € 623,2 Mio. So gesehen könnte die herrschende Konzern-Mittelfristperspektive angehoben werden, sofern die anlaufende 2. Corona-Welle nicht ...

Jehanne Leroy

Sartorius Stedim Biotech - AGM du 24 mars 2021

Rémunérations 2020 (résolution 7) : Les montants attribués au titre de l’exercice 2020 à M. Kreuzburg sont acceptables et bien en ligne avec les bonnes performances du groupe sur l’exercice. Nous soutenons donc la résolution 7. Nous encourageons toutefois la société à améliorer sa transparence et à communiquer les taux de réalisation de chacun des critères du bonus comme c’est désormais la pratique dans le SBF 120. Rapport rémunérations (résolution 6)S’il est appréciable que la société ait entendu les remarques de Proxinvest et ait communiqué cette année les ratios d’équité, on regrettera tou...

Expert Corporate Governance Service (ECGS)

Sartorius Stedim Biotech – AGM 24 June 2020

Changes published in the press release of 13/5/20 : - modification of the dividend from €0.64 to €0.35   ITEMS 6 AND 7: ECGS recommends to oppose the remuneration report and the "ex-post" remuneration of Joachim Kreuzburg which we deem excessive and which lacks transparency. ITEM 8: the same issues of transparency lead ECGS to also oppose the "ex-ante" remuneration policy. ITEM 4: Like last year, the Company did not make public many details on the Related-party Agreements report. This includes information on the ties between the Company and Sartorius AG (its largest shareholder) and this ...

Expert Corporate Governance Service (ECGS)

Sartorius Stedim Biotech, March 26 2019

Item 9: This year, the re-election of Joachim Kreuzburg, CEO, as director is up for vote. ECGS recommends opposing this item due to the lack of counter-power and the absence of information regarding performance and environmental issues. Item 4: Much like last year, the Company did not make public many details on the Related- party Agreements report. This includes information on the tie between the Company and Sartorius AG (their main shareholder) and the lack of transparency is a serious breach against other shareholders rights.

Florian Béchaz

Sartorius Stedim Biotech, 26 Mars 2019

Proxinvest attire l'attention des actionnaires sur différents points lors de cette assemblée générale. Tout d'abord le renouvellement de Joachim Kreuzburg. Ce dernier est le Président Directeur Général de la société. Proxinvest a donc analysé la présence de contre-pouvoirs, la performance économique et la performance environnementale. Bien que la performance boursière soit à saluer, les autres éléments ne permettent pas une recommandation positive. Ensuite, comme l'année précédente, le fait que seulement une partie des transactions liant la société et Sartorius AG, son premier actionnaire, s...

Sartorius Stedim Biotech - Assemblée générale des actionnaires du 26 mars 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Jean-Baptiste Rouphael ...
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/27/2021

...

Alfred Glaser ...
  • Delphine Brault

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/10/2020

...

Bruno Cavalier ...
  • Christophe-Raphaël Ganet

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/05/2020

After an atypical year marked by an unprecedented slump in electricity consumption, the conditions have come together for electricity prices to resume an upward trajectory. In our view, the ecological shift enshrined in the European stimulus plans will be conducive to a return to earnings growth. The “green” premium is set to underpin the stock, bearing in mind that consensus revisions are now geared more to the upside. Rating raised to Buy from Reduce, with the target price raised to...

Bruno Cavalier ...
  • Christophe-Raphaël Ganet

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 05/10/2020

Après une année atypique marquée par une chute historique de la consommation d’électricité, les conditions sont maintenant réunies pour que les prix de l’électricité reprennent une tendance haussière. Le virage écologique des plans de relance nous semble propice à un retour de la croissance des résultats. La prime "verte" devrait soutenir le cours sachant que les risques de révision du consensus sont désormais plutôt orientés à la hausse. Opinion relevée à Achat vs Alléger, OC relevé ...

SARTORIUS STEDIM BIOTECH suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of SARTORIUS STEDIM BIOTECH (FR), active in the Medical Supplies industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date November 10, 2020, the closing price was EUR 299.60 and its target price was ...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

Dominic Rose ...
  • Naresh Chouhan

Global CDMOs - Impact of Alzheimer's Windfall

Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact on the industry of a potential Alzheimer’s windfall from Biogen’s aducanumab. As the FDA filing draws closer, Biogen are likely to be involved in intense negotiations to find alternative sources of supply. Our highly detailed analysis shows how much aducanumab will need to be produced, who the winners are likely to be, the revenue uplift they may enjoy and the NPV uplift to each player. Lonza & Samsung Biologics are likely the biggest winners with Catalent close behind.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch